Skip to content
10-Q

Quarterly Report

PARDES BIOSCIENCES, INC.

0000950170-23-018303

← back to feed
Filed
May 5, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · May 1, 2023 61.72M sh
Shares Diluted Q3 2023 · Mar 31, 2023 59.77M sh
Shares Diluted Q3 2023 · Mar 31, 2022 57.04M sh
Operating Cash Flow Q3 2023 · Mar 31, 2023 −$26.53M
Operating Cash Flow Q3 2023 · Mar 31, 2022 −$20.36M
Short Term Investments Q3 2023 · Mar 31, 2023 $125.07M
Short Term Investments Q3 2023 · Dec 31, 2022 $138.06M
Cash And Equivalents Q3 2023 · Mar 31, 2023 $47.16M
Cash And Equivalents Q3 2023 · Dec 31, 2022 $59.28M
Stockholders Equity Q3 2023 · Mar 31, 2023 $164.73M
Stockholders Equity Q3 2023 · Dec 31, 2022 $180.2M
Stockholders Equity Q3 2023 · Mar 31, 2022 $246.38M
Stockholders Equity Q3 2023 · Dec 31, 2021 $266.29M
Current Liabilities Q3 2023 · Mar 31, 2023 $11.42M
Current Liabilities Q3 2023 · Dec 31, 2022 $20.43M
Total Liabilities Q3 2023 · Mar 31, 2023 $11.42M
Total Liabilities Q3 2023 · Dec 31, 2022 $20.43M
Current Assets Q3 2023 · Mar 31, 2023 $176.15M
Current Assets Q3 2023 · Dec 31, 2022 $200.4M
Total Assets Q3 2023 · Mar 31, 2023 $176.15M
Total Assets Q3 2023 · Dec 31, 2022 $200.62M
Eps Diluted Q3 2023 · Mar 31, 2023 −$0.30
Eps Diluted Q3 2023 · Mar 31, 2022 −$0.38
Eps Basic Q3 2023 · Mar 31, 2023 −$0.30
Eps Basic Q3 2023 · Mar 31, 2022 −$0.38
Rd Expense Q3 2023 · Mar 31, 2023 $12.98M
Rd Expense Q3 2023 · Mar 31, 2022 $13.2M
Net Income Q3 2023 · Mar 31, 2023 −$17.81M
Net Income Q3 2023 · Mar 31, 2022 −$21.44M